Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Immunology

Background:

• Atherosclerosis is a primary cause of ischemic cardiovascular and cerebrovascular diseases.
• Signal transducer and activator of transcription 3 (STAT3) plays a critical role in atherosclerosis pathogenesis.
• Aberrant STAT3 activation is implicated in the development and progression of atherosclerosis.

Purpose of the Study:

• To review the multifaceted roles of STAT3 in atherosclerosis.
• To summarize and classify STAT3 inhibitors as potential therapeutic agents.
• To identify challenges and propose solutions for STAT3 inhibitor-based atherosclerosis therapies.

Main Methods:

• Literature review of STAT3's role in endothelial dysfunction, macrophage polarization, inflammation, and immunity.
• Analysis of STAT3's involvement in mitochondrial function during atherosclerosis.
• Classification and summary of existing STAT3 inhibitors.
• Discussion of therapeutic challenges and future directions.

Main Results:

• STAT3 significantly influences key processes in atherosclerosis, including endothelial cell function, macrophage behavior, and immune responses.
• STAT3's role extends to mitochondrial pathways involved in atherosclerosis.
• A range of STAT3 inhibitors have been identified, offering potential therapeutic avenues.
• Obstacles to developing mature STAT3 inhibitor therapies for atherosclerosis were identified.

Conclusions:

• STAT3 is a key mediator in atherosclerosis, making it a promising therapeutic target.
• STAT3 inhibitors represent a potential strategy for treating atherosclerosis.
• Overcoming current developmental challenges is crucial for realizing the clinical potential of STAT3 inhibitors in atherosclerosis treatment.